Home » Consultants

Dr Pierre Thirion

Dr Pierre Thirion, Consultant Radiation Oncologist, MD, DES Radiotherapy, DESC Medical Oncology, FFRRCSI.

Dr Pierre Thirion, is a French trained radiation oncologist, presently holding a permanent specialist consultant position in St Luke’s Hospital, Dublin, and chairperson of the Radiation Oncology department.

Dr Thirion completed his basic medical training at the University Paris V-René Descartes medical school. He completed his Fellowship in Radiation Oncology (University Paris-V), rotating through the main Parisian radiotherapy departments. In 1998, he completed an additional diploma in medical oncology (University Paris-XI). After working for two years as a Chef de Clinique des Universités – Assistant des Hôpitaux de Paris (Henri Mondor Hospital, Créteil, France), he moved to Ireland in 1999 and took a position of Clinical/Research Senior Registrar in St Luke’s Hospital, Dublin. Since 2002, he has been working as a Consultant Radiation Oncologist at the latter hospital.

Dr Thirion has a special interest in the treatment of prostate and other genito-urinary cancer, lung tumour, breast cancer, gastro-intestinal malignancies and lymphoma. He has a recognised expertise in new radiotherapy technologies, including IMRT and brachytherapy, and had a major role in the implementation and development of extra-cranial stereotactic radiation therapy in Beacon Hospital. Dr Thirion completed a MD in radiobiology at the Curie Research Institute, Paris (University Paris XI-Paris Sud, 1996) and a post-graduate diploma in statistics (Trinity College Dublin, 2002). His present areas of research and publications include:

• clinical trials methodology and meta-analyses

• the development of new radiotherapy technologies

• the implementation radiotherapy-oriented clinical trials.

He is the principal investigator of several national and international clinical trials, and is an executive member of the All Ireland Cooperative Oncology Research Group (ICORG) and other international research group (EORTC).

Dr Alina Mihai

Consultant Radiation Oncologist MD MSc

UCD Clinical Assistant Professor

Director of Oncology Research

Prof. Alina Mihai is a full time Consultant Radiation Oncologist at Beacon Hospital, UCD Clinical Assistant Professor and our Director of Oncology Research. She founded the annual Irish SRS/SBRT Symposium which continues to expand and is recognized internationally. She is the Scientific Program Chair and Head of the Organising Committee. She is also part of the Scientific and Organising Committee of the Annual Best of ASCO-Best of ASTRO meeting, taking place in Romania since 2016.

Dr. Mihai completed her Medical Degree and Specialty in Romania followed by clinical and research Fellowships in France (University of Rouen – Prof B. Dubray) and Canada. Between 2002-2005, while at the University of Toronto, she was involved in the development of forward planning IMRT for breast cancer and involved in assessing the role of central pathology review in DCIS breast.

Between 2006-2007 Dr Mihai joined the Cross Cancer Institute in Edmonton (Alberta), initially as a Clinical Research fellow, and subsequently as a full time locum Consultant. During this period she was involved in developing the tomotherapy technique for breast cancer treatments, as well as in implementing the PET-CT and myocardial perfusion scans in the process of radiotherapy planning for lung and breast malignancies. Dr Mihai joined Beacon Hospital in July 2007.

Dr. Mihai had a pivotal role in the implementation and development of gated and image guided radiotherapy and stereotactic body radiotherapy at Beacon Hospital, and leads the extracranial SBRT task group at Beacon Hospital. Her expertise is in assessment of moving targets, SBRT for oligometastatic disease and IMRT for brain, prostate and lung cancers. Dr Mihai earned her Master degree in Radiation Science (University of Toronto) in 2006. Her present areas of research and publications include SBRT for oligometastatic disease and SBRT in the elderly as well as the role of metabolic imaging in treatment planning and response assessment. She published several peer reviewed articles on these subjects, was co-author in two chapters of a recently published boon on stereotactic radiosurgery and stereotactic ablative radiotherapy. She reported extensively on Beacon radiotherapy experience with SRS/SBRT at internationally recognized meetings in Europe and USA. She is member of several professional organizations including Cancer Trials Ireland, ESTRO, ASTRO, EANO.

Under her supervision, the Division of Oncology Research increased significantly its activity, currently running 18 national and international multicentric trials. Dr. Mihai is the national PI for three international multicentric trials, and site PI for other five national and international trials. ASTRO recently highlighted the ICORG 15-05/UPCI 10-028 clinical trial on the role of SABR for patients with oligo-recurrent solid cancers. As part of this trial, 31 Irish patients were recruited by Beacon Oncology Research Unit.

Professor John G. Armstrong

Professor John G. Armstrong, Consultant Radiation Oncologist, MD FRCPI DABR FFRRCSI.

Professor John Armstrong is a Board Member and ex-chairman of the Irish Cancer Society. Professor Armstrong was trained at Memorial Sloan-Kettering Cancer Center, where he performed his residency and was Chief resident, attending for five years. He directed the lung cancer radiation research programme at Memorial Sloan-Kettering Cancer Center, and co-authored the chapter on non-small cell lung cancer chapter in 4th edition of DeVita, Hellman, and Rosenberg, Cancer: Principles and Practice of Oncology, Lippincott.

He is currently the Director of Research at St. Luke’s Hospital, Dublin. Professor Armstrong is the Principal Investigator for several clinical trials in the Irish Clinical Oncology Research Group.

Professor Armstrong has published numerous articles and has lectured extensively in the field of radiation oncology. He has been instrumental in the rollout of new procedures involving high-tech radiation therapy procedures such as Intensity Modulated Radiation Therapy, and stereotactic radiosurgery.